PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'STAT-Dx Life, S.L. (a QIAGEN Company), Baldiri Reixac, 4-8, 08028 Barcelona, Spain.\', \'QIAGEN, Inc., 19300 Germantown Road, Germantown, MD 20874, USA.\', \'QIAGEN Manchester Ltd, Skelton House, Lloyd Street North, Manchester, M15 6SH, UK.\', \'STAT-Dx Life, S.L. (a QIAGEN Company), Baldiri Reixac, 4-8, 08028 Barcelona, Spain. Electronic address: marta.lopez@qiagen.com.\', \'STAT-Dx Life, S.L. (a QIAGEN Company), Baldiri Reixac, 4-8, 08028 Barcelona, Spain. Electronic address: josep.pareja@qiagen.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1201-9712(20)30463-X10.1016/j.ijid.2020.06.027
?:doi
?:hasPublicationType
?:journal
  • International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
is ?:pmid of
?:pmid
?:pmid
  • 32535302
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all